Sign In
Buy AORT
$26.83
-0.84 (-3.04%)
At Close: Jul 31, 2026
Artivion Reports First Quarter 2026 Financial Results and Announces Exercise of Option to Acquire Endospan
04:05pm, Thursday, 07'th May 2026
First Quarter & Recent Business Highlights: Achieved revenue of $116.3 million in the first quarter of 2026 versus $99.0 million in the first quarter of 2025, an increase of 18% on a GAAP basis and 12
Artivion Announces Release Date and Teleconference Call Details for First Quarter 2026 Financial Results
04:15pm, Thursday, 23'rd Apr 2026
ATLANTA, April 23, 2026 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, announced today that first quarter 2026 financial results
Head-To-Head Comparison: Pressure BioSciences (OTCMKTS:PBIO) and Artivion (NYSE:AORT)
01:26am, Monday, 13'th Apr 2026
Pressure BioSciences (OTCMKTS:PBIO - Get Free Report) and Artivion (NYSE: AORT - Get Free Report) are both small-cap medical companies, but which is the better business? We will compare the two compan
Artivion Secures FDA Approval for NEXUS Aortic Arch System
11:35am, Wednesday, 08'th Apr 2026
AORT jumps after FDA approves NEXUS Aortic Arch System, unlocking a potential Endospan acquisition and advancing minimally invasive care for high-risk patients.
Artivion (AORT) Soars 5.3%: Is Further Upside Left in the Stock?
04:47am, Wednesday, 08'th Apr 2026
Artivion (AORT) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the ro
Artivion Announces U.S. FDA Approval of the NEXUS® Aortic Arch System
07:00am, Tuesday, 07'th Apr 2026
Endospan's NEXUS branched endovascular stent graft system shown to effectively treat aortic arch disease, including chronic aortic dissections ATLANTA, April 7, 2026 /PRNewswire/ -- Artivion, Inc. (NY
SG Americas Securities LLC Raises Stake in Artivion, Inc. $AORT
05:03am, Monday, 06'th Apr 2026
SG Americas Securities LLC boosted its position in shares of Artivion, Inc. (NYSE: AORT) by 578.4% in the undefined quarter, according to its most recent filing with the Securities and Exchange Commis
Artivion (NYSE:AORT) Shares Gap Down – Should You Sell?
03:49am, Saturday, 04'th Apr 2026
Artivion, Inc. (NYSE: AORT - Get Free Report)'s stock price gapped down prior to trading on Thursday. The stock had previously closed at $36.62, but opened at $33.60. Artivion shares last traded at $3
Artivion, Inc. (NYSE:AORT) Receives Consensus Rating of “Moderate Buy” from Analysts
04:24am, Saturday, 28'th Mar 2026
Shares of Artivion, Inc. (NYSE: AORT - Get Free Report) have received an average rating of "Moderate Buy" from the eight research firms that are presently covering the firm, Marketbeat Ratings reports
Artivion to Participate in the Oppenheimer 36th Annual Healthcare MedTech & Services Conference
04:10pm, Tuesday, 03'rd Mar 2026
ATLANTA, March 3, 2026 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, announced today that it will participate virtually at th
Artivion, Inc. (AORT) Q4 2025 Earnings Call Transcript
11:04pm, Thursday, 12'th Feb 2026
Artivion, Inc. (AORT) Q4 2025 Earnings Call Transcript
Artivion (AORT) Q4 Earnings Surpass Estimates
06:31pm, Thursday, 12'th Feb 2026
Artivion (AORT) came out with quarterly earnings of $0.17 per share, beating the Zacks Consensus Estimate of $0.14 per share. This compares to break-even earnings per share a year ago.
Artivion Reports Fourth Quarter and Full Year 2025 Financial Results
04:05pm, Thursday, 12'th Feb 2026
Fourth Quarter Highlights: GAAP revenue was $116.0 million in the fourth quarter of 2025 versus $97.3 million in the fourth quarter of 2024. For the full year, GAAP revenue was $441.3 million versus $
Artivion (AORT) to Release Earnings on Thursday
02:52am, Thursday, 05'th Feb 2026
Artivion (NYSE: AORT - Get Free Report) is expected to announce its Q4 2025 results after the market closes on Thursday, February 12th. Analysts expect the company to announce earnings of $0.14 per sh
1-Year Data from Endospan's NEXUS TRIOMPHE IDE Trial Demonstrate High Patient Survival with Low Morbidity 2-Year Data from the AMDS PERSEVERE IDE Trial Further Demonstrate the Persistent Clinical Bene
